




Supplementary Figure 1 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups before propensity score matching. A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval.



Supplementary Figure 2 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups receiving the "platinum-taxane combination regimen". A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval.



Supplementary Figure 3 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups receiving the "SOX or XELOX regimens". A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval.



Supplementary Figure 4 The recurrence patterns. A: In the HIPEC+AC group included peritoneal metastasis ($n = 20$; 20.83%), local recurrence ($n = 11$; 10.46%), and distant metastasis ($n = 19$; 19.79%); B: In the AC group developed peritoneal metastases ($n = 43$, 33.33%), local recurrence ($n = 19$, 14.73%), and distant metastases ($n = 29$, 27.13%).